• Loading stock data...
Est. 2004

LEVERAGE OUR MASSIVE INVESTOR AUDIENCE!

Stock Investors · Accredited Investors · Hedge Fund Investors

Learn More or Call (407) 374-6986

Monday 12/10/2018
SMALL CAP MARKET NEWS

We release small market news updates daily, 5 times a week! Always check back to get the inside scoop on what going on.


LEVERAGE OUR MASSIVE INVESTOR AUDIENCE!

Stock Investors · Accredited Investors · Hedge Fund Investors

Learn More

INNV

  • 5:07 PM

    ProstaGorx is the Ninth Innovus Pharma Product Approved in Canada to Date SAN DIEGO, June 04, 2018 (GLOBE NEWSWIRE) — Via OTC PR Wire – Innovus Pharmaceuticals, Inc. (“Innovus Pharma” or the “Company”) (OTCQB Venture Market:INNV), an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men’s and women’s health and respiratory diseases, today announced the approval by Health Canada of its product ProstaGorx as a Natural Health Product (NPN # 80085717) for

    Read more
  • 7:33 AM

    May 09, 2017, INNV OTC Disclosure & News Service – Innovus Pharmaceuticals, Inc. (the “Company” or “Innovus Pharma”) (OTCQB Venture Market: INNV) and its partner West-Ward Pharmaceuticals International Limited (“WWPIL”), a wholly-owned subsidiary of Hikma Pharmaceuticals PLC (“Hikma”) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), today announced that WWPIL will provide the Company with the rights to launch its branded, fluticasone propionate nasal spray USP, 50 mcg per spray (FlutiCare™), under WWPIL’s FDA approved abbreviated new drug application (“ANDA”) No.

    Read more
  • 2:45 PM

    Company in a Strong Cash Position for Product Launches and Expedited Growth SAN DIEGO, CA– INNV, (Marketwired – Aug 1, 2016) – Innovus Pharmaceuticals, Inc. (“Innovus Pharma” or the “Company) www.innovuspharma.com (OTCQB: INNV), a company focusing on the commercialization of over-the-counter (“OTC”) and consumer products for men’s and women’s health, vitality and respiratory diseases, announced today, the closing of its previously announced $3 million private financing from institutional investors. “Our ability to attract high caliber institutional investors into the Company

    Read more
  • 12:56 PM

    Company on Track to Be Being Cash Flow Positive Exiting 2016 SAN DIEGO, CA–INNV, (Marketwired – Jun 15, 2016) – Innovus Pharmaceuticals, Inc. (“Innovus Pharma” or the “Company”) www.innovuspharma.com (OTCQB: INNV), a company focusing on the commercialization of over-the-counter (“OTC”) and consumer products for men’s and women’s health, vitality and respiratory diseases, announced today that the Company has reduced its debt obligation by $1.5 million and also eliminated approximately $300k in derivative liabilities as of 3/31/16, resulting in a total

    Read more
  • 4:06 PM

    Innovus Pharma’s Aggregate Annual Revenues Expected to Triple to Close to $4.0 Million SAN DIEGO, CA–INNV, (Marketwired – Mar 1, 2016) – Innovus Pharmaceuticals, Inc., (“Innovus Pharma” or the “Company) www.innovuspharma.com (OTCQB: INNV) a company focusing on the commercialization of over-the-counter (“OTC”) and consumer products for men’s and women’s health, vitality and respiratory diseases, announced today the closing of the acquisition for substantially all of the assets of Beyond Human, for a cash purchase price of $630,000. In order to

    Read more
Public Wire Banner